A

*click HERE for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 Link to Formulary

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
5-aminolaevulinic acid (as hydrochloride) 78mg/g gel (Ameluz®) SMC No. (1260/17)	Treatment of superficial and / or nodular basal cell carcinoma (BCC) unsuitable for surgical treatment due to possible treatment-related morbidity and / or poor cosmetic outcome in adults.	Not available as not recommended for use in NHS Scotland	163 167	Sep 2017 April 2018
Abacavir (Ziagen®)	HIV	Hospital Only	50	2005
Abacavir/lamivudine (Kivexa®)	HIV	Hospital Only	50	2005
Abatacept 125mg solution for injection (pre-filled syringe); 125mg solution for injection in pre-filled pen; 250mg powder for concentrate for solution for infusion (Orencia®) SMC No 1287/17	Alone or in combination with methotrexate for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy including methotrexate has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not required.	Not available as not recommended for use in NHS Scotland	165	Jan 2018
Abatacept (Orencia®) (1230/17)	Treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.	Not available as not recommended for use in NHS Scotland	160	Apr 2017
Abatacept (Orencia®) (888/13)	In combination with methotrexate, for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs including methotrexate or a TNF-alpha inhibitor.	Hospital Only (4th line agent)	129	Aug/Sep 2013
Abatacept (Orencia®) (618/10)	Juvenile idiopathic arthritis	Hospital Only (Paediatric Rheumatology Clinic)	112 96	Dec 2011 Apr/May 2010

Abatacept (Orencia®) (719/11)	Moderate to severe active rheumatoid arthritis	Hospital Only	127 110 72	May 2013 Oct 2011 Sep 2007
Abemaciclib 50mg, 100mg and 150mg film-coated tablets (Verzenios®) SMC2494	In combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. In pre- or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. In an open-label, randomised, phase III study, the addition of abemaciclib to adjuvant endocrine therapy improved invasive disease-free survival (IDFS) compared with endocrine therapy alone in patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. The cohort of study patients with at least four positive axillary lymph nodes or one to three positive axillary lymph nodes plus either grade 3 disease and/or tumour size ≥5cm supported the evidence for patients of high risk of recurrence in clinical practice.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	192	Nov 22
Abemaciclib 50mg, 100mg and 150mg tablets (Verzenios®) SMC2135	For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor* as initial endocrine-based therapy, or in women who have received prior endocrine therapy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	175	Aug 2019
Abemaciclib 50mg, 100mg and 150mg tablets (Verzenios®) SMC2179	For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with fulvestrant* as initial endocrine-based therapy or in women who have received prior endocrine therapy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	175	Aug 2019

	SMC restriction: for use in women who have progressed on or after (neo) adjuvant endocrine therapy, or progressed during first-line endocrine-based therapy for advanced breast cancer			
Abiraterone (Zytiga®) (873/13)	With prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.	Available in line with national guidance	146 127 152 157	Feb 2015 May 2013 Nov/Dec 2015 Nov 2016
Abiraterone acetate 500mg film-coated tablets (Zytiga®) - SMC 2215	Abiraterone acetate with prednisone or prednisolone for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer in adult men in combination with androgen deprivation therapy.	Approved in line with national guidance.	179	Apr 2020
Abiraterone acetate 250mg tablets (Zytiga®)	With prednisone or prednisolone for treatment of metastatic castration resistant prostrate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is no yet clinically indicated.	Formulary Hospital Use only (Oncology)	153	Jan/Feb 2016
Abiraterone acetate (Zytiga®) (764/12)	With prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.	Hospital Only (Oncology)	119 116	Aug/Sept 2012 Apr/May 2012
Abrocitinib 50mg, 100mg, and 200mg film-coated tablets (Cibinqo®) SMC 2431	For the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. SMC restriction: for use in patients who have not responded to, or have lost response to, at least one systemic immunosuppressant therapy, or in whom these are contraindicated or not tolerated. Four phase III studies demonstrated superiority of	Available in line with local guidance for prescribing	190	August 2022

	abrocitinib in improving signs and symptoms of atopic dermatitis when compared with placebo, as monotherapy or in combination with medicated topical therapies in patients with moderate to severe atopic dermatitis.			
Acalabrutinib 100mg hard capsules (Calquence®) SMC2347	As monotherapy or in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). SMC restriction: as monotherapy for the treatment of adult patients with previously untreated CLL without a del(17p) or TP53 mutation and who are ineligible for fludarabine, cyclophosphamide and rituximab (FCR) therapy	Available in line with national guidance	185	July 2021
Acalabrutinib 100mg hard capsules (Calquence®) SMC2346	Indication under review: as monotherapy or in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). SMC restriction: as monotherapy for the treatment of adult patients with previously untreated CLL who have a 17p deletion or TP53 mutation and in whom chemo-immunotherapy is unsuitable. Acalabrutinib offers an additional treatment choice in the therapeutic class of Bruton tyrosine kinase inhibitor in this setting. Another medicine within this therapeutic class has been accepted via the end of life and orphan medicine process.	Available in line with national guidance	184	May 2021
Acalabrutinib 100mg hard capsules (Calquence®) SMC2348	Indication under review: As monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. SMC restriction: For adults with relapsed/refractory CLL who have had at least one previous therapy, in whom chemo-immunotherapy is unsuitable. Acalabrutinib offers an additional treatment choice in the	Available in line with national guidance	184	May 2021

	therapeutic class of BTK inhibitor in this setting. Another medicine within this therapeutic class has been accepted via the end of life and orphan medicine process.			
Aclidinium/formoterol fumarate dihydrate (Duaklir Genuair®) (1034/15)	Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.	Formulary	147	Apr 2015
Aclidinium (Eklira Genuair®) (810/12)	COPD	Formulary	123 122	Jan 2013 Dec 2012
Adalimumab 40mg/0.4mL pre-filled syringe and pre-filled pen / adalimumab 40mg/0.4mL 40mg/0.8mL vial for paediatric use (Humira®) SMC No 1305/18	Treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.	Not available as not recommended for use in NHS Scotland	167	April 2018
Adalimumab, 40mg/0.4mL pre-filled syringe (Humira®) and pre-filled pen adalimumab, 40mg/0.8mL vial for paediatric use (Humira®) SMC No. (1243/17)	Treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	162	Aug 2017
Adalimumab 40mg/0.4ml Pre-filled Syringe and Pre-filled Pen & Adalimumab 40mg/0.8ml Pre-filled Syringe and Pre-filled Pen (Humira®) SMC 1209/16	Treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate	Not available as not recommended for use in NHS Scotland	158	Dec 2016
Adalimumab 40mg/0.4ml Pre-filled Syringe and Pre-filled Pen & Adalimumab 40mg/0.8ml vial for paediatric use (Humira®) SMC 1208/16	Treatment of moderately active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies	Not available as not recommended for use in NHS Scotland	158	Dec 2016

Adalimumab (Humira®) 1173/16	Treatment of moderate to severe chronic plaque psoriasis on adult patients who are candidates for systemic therapy. (This licence extension relates to previous SMC advice 468/08).	Not available as not recommended for use in NHS Scotland	156	Sep 2016
Adalimumab 40mg/0.8ml solution for injection (Humira®) SMC 1143/16	Treatment of active moderate to severe hidradenitis suppurative (HS) (acne inversa) in adult patients with inadequate response to conventional HS therapy	Available in line with National guidance	155	June 2016
Adalimumab (Humira®) (1050/15)	For the treatment of active enthesitis-related arthritis in patients, 6 years or age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy.	Hospital Use Only (Paediatric Rheumatology) (Will not appear in TAF which is an adult formulary)	148	May 2015
Adalimumab (Humira®) (1068/15)	Treatment of severe chronic plaquepsoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy andphototherapies.	Non Formulary Lack of clinician demand	150	June 2015
Adalimumab (Humira®) (880/13)	Severe active Crohn's disease (6 to 17 years)	Hospital Only (Paediatric Gastroenterology)	129	Aug/Sep 2013
Adalimumab (Humira®) (881/13)	Active polyarticular juvenile idiopathic arthritis (2 to 17 years)	Hospital Only (Paediatric Rheumatology)	129	Aug/Sep 2013
Adalimumab (Humira®) (858/13)	Severe axial spondyloarthritis	Hospital Only	127	May 2013
Adalimumab (Humira®) (824/12)	Moderately active Crohn's disease	Not recommended	122	Dec 2012
Adalimumab (Humira®) (800/12)	Ulcerative colitis	Not recommended	119	Aug/Sep 2012
Adalimumab (Humira®) (738/11)	Active polyarticular juvenile idiopathic arthritis in children and adolescents (4-17 years)	Hospital Only (Paediatric Rheumatology Clinic)	112	Dec 2011
Adalimumab (Humira®) (533/09)	Adolescents with active polyarticular juvenile idiopathic arthritis (13-17 years) in combination with methotrexate	Hospital Only (Paediatric Rheumatology Clinic)	86	Jan 2009

Adalimumab (Humira®)	Chronic plaque psoriasis	Hospital Only	80	June 2008
Adalimumab (Humira®) (417/07)	Severe, active Crohn's disease	Hospital Only (GI Clinic)	122 74	Dec 2012 Nov 2007
Adalimumab (Humira®)	Severe active ankylosing spondylitis	Hospital Only (Rheumatology Clinic)	64	2006
Adalimumab (Humira®)	Rheumatoid arthritis	Hospital Only (Rheumatology Clinic)	34	2003
Adalimumab (Humira®)	Psoriatic arthritis	Hospital Only	55	2006
Adapalene (Epiduo®) (682/11)	Acne vulgaris	Non-formulary - absence of clinician demand	137 104	Apr/May 2014 Mar 2011
Adefovir (Hepsera®)	Chronic Hepatitis B	Hospital Only	50 29	2005 2003
Adrenaline tartrate (Jext®) (687/11)	Severe acute allergic reactions	Formulary	111	Nov 2011
Afamelanotide 16mg implant (Scenesse®) SMC (1251/17)	Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP)	Not available as not recommended for use in NHS Scotland. 'Available within ultra orphan pathway while further evidence on effectiveness is generated	183 Protocol	March 2021
Afatainib (Giotrif®) 174/16	As monotherapy for the treatment of locally advanced or metastatic non small cell lung cancer of aquamous histology progressing on or after platinum based chemotherapy.	Not available as not recommended for use in NHS Scotland	156	Sep 2016
Afatinib (Eylea®) (954/14)	For adults for treatment of visual impairment due to macular oedema	Hospital Only	137	Apr/May 2014
Afatinib (Giotrif®) (920/13)	Adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s)	Hospital Only (Oncology)	136	Mar/Apr 2014

amivantamab (Rybrevant) SMC2638	as monotherapy for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.	Not available as not recommended for use in NHS Scotland	196	February 2024
Aflibercept 40mg/ml solution for injection (Eylea®) SMC 1186/16	For adults for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV).	Available in line with local guidance.	158	Dec 2016
Aflibercept (Eylea®) (1074/15)	For adults for the treatment of visual impairment due to macular oedema secondary to branch retinal vein occlusion	Formulary Hospital Only Ophthalmology Specialist Formulary List	151	Sep/Oct 2015
Aflibercept (Eylea®) (1003/14)	For adults for the treatment of visual impairment due to diabetic macular oedema (DMO). SMC restriction: treatment of visual impairment due to DMO in adults with best corrected visual acuity (BCVA) 75 Early Treatment Diabetic Retinopathy Study (ETDRS) letters or less at baseline	Formulary 2nd line choice for DMO in patients unresponsive to ranibizumab treatment Hospital Only	143	Nov/Dec 2014
Aflibercept (Zaltrap®) (878/13)	Metastatic colorectal cancer (mCRC)	Hospital Only (Oncology)	136 129	Mar/Apr 2014 Aug/Sep 2013
Aflibercept (Eylea®) (954/14)	For adults for treatment of visual impairment due to macular oedema	Hospital Only 2nd line choice	137	Apr/May 2014
Aflibercept (Eylea®) (857/13)	Neovascular (wet) age-related macular degeneration	Hospital Only (Opthalmology Specialist List)	127 139	May 2013 Jun/Jul 2014

Agomelatine (Valdoxan®) (564/09) Aflibercept solution for injection in pre-filled syringe (Eylea®) SMC2612	Major depressive disorders in adults In preterm infants for the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease.	Not recommended Not recommended	99 93 194	Aug/Sep 2010 Oct/Nov 2009 September 2024
Albiglutide 30mg and 50mg pre-filled pen (Eperzan®) SMC No. 1024/15	Treatment of type 2 diabetes mellitus in adults to improve glycaemic control in combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. SMC Restriction: an alternative once weekly glucagon-like peptide-1 (GLP-1) agonist for use in combination with oral anti-diabetic agents as a third-line pre-insulin treatment option.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	153 154	Jan/Feb 2016 May 2016
alectinib hard capsules (Alecensa®) SMC2749	as monotherapy as adjuvant treatment for adult patients with Stage IB (tumours ≥ 4 cm) to IIIA (7th edition of the UICC/AJCC-staging system) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) following complete tumour resection. In an open-label phase III study, alectinib was associated with a statistically significant improvement in disease-free survival compared with platinum-based chemotherapy following surgery in patients with early ALK-positive NSCLC.	Available in line with national guidance.		

Alectinib 150mg hard capsules (Alecensa®) SMC No 2012 following a full submission assessed under orphan medicine process	As monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Alectinib, compared with another tyrosine kinase inhibitor, significantly improved progression-free survival in treatment-naïve adults with advanced or recurrent ALK-positive NSCLC.	Available in line with National Guidance	170	Sep 2018
Alectinib hydrochloride, 150mg hard capsules (Alecensa®) SMC No: (1257/17)	As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer previously treated with crizotinib	Not available as not recommended for use in NHS Scotland	162	Aug 2017
Alendronic acid 70mg effervescent tablet (Binosto®) SMC 1137/16	Treatment of postmenopausal osteoporosis. SMC Restriction: for use in patients who are unable to swallow tablets where alendronic acid is the appropriate treatment choice.	Available in line with National Guidance	155	Jun 2016
Alemtuzumab (Lemtrada®) (959/14)	For adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.	Available in line with local guidance for prescribing	140	Jul/Aug 2014
Alemtuzumab (MabCampath®) (494/08)	B-cell chronic lymphocytic leukaemia (B-LL)	Hospital Only	82	Aug/Sep 2008
Alendronate/colecalciferol (Fosavance®)	Postmenopausal osteoporosis	Non-formulary	54	2005
Alglucosidase alfa (Myozyme®) 9352/07)	Pompe disease	Not recommended	67	Mar 2007
alirocumab 75mg / 150mg solution for injection in pre-filled pen (Praluent®) SMC2201	In adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: • in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,	Not available as not recommended for use in NHS Scotland	175	Aug 2019

	• alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.			
Alirocumab 75mg and 150mg solution for injection in prefilled pen (Praluent®)	Adults with primary hypercholesterolaemia (heterozygous familial and non familial) or mixed dyslipidaemia, as an adjunct to diet: in combination with a statin and other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of statin or, alone or in combination with other lipid lowering therapies in patients who are statin intolerant or for whom a statin is contra-indicated.	Available in line with local guidance for prescribing (Link to Formulary)	156	Sep 2016
Aliskiren (Razilex®) (462/08)	Essential hypertension	Not recommended	114 95 86 79	Feb 2012 Feb/Mar 2010 Jan 2009 May 2008
Alitretinoin (Toctino®) (538/09)	Severe chronic hand eczema	Hospital Only (Dermatology Clinic)	87	Mar 2009
Alpelisib 50mg, 150mg, 200mg film-coated tablets (Piqray®) SMC2481	In combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine-based therapy. The addition of alpelisib to fulvestrant significantly increased progression-free survival in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer with PIK3CA mutation.	Not available as not recommended for use in NHS Scotland		
Alogliptin (Vipodomet®) (998/14)	Adult patients aged 18 years and older with Type 2 diabetes mellitus	Non-formulary - absence of clinician demand	142	Oct/Nov 2014
Alogliptin (Vipidia®) (937/14)	Type 2 diabetes mellitus in adults	Non-formulary - absence of clinician demand	141	Sep/Oct 2014 Mar/Apr 2014

			136	
Alteplase (Actilyse Cathflo®) (714/11)	Acute ischaemic stroke	Hospital Only (NW Stroke unit/A&E, PRI Gen Med) Stroke specialist list	118	July 2012
Alteplase (Actilyse Cathflo®) (717/11)	Thrombolytic treatment of occluded central venous access devices	Non-formulary - absence of clinician demand	113 109	Jan 2012 Sep 2011
Alteplase (Actilyse®) (87/04)	Acute ischaemic stroke	Hospital Only	37	2004
Ambrisentan (Volibris®) (511/08)	Class II and III pulmonary arterial hypertension		84	Nov 2008
Amifampridine (Firdapse®) (660/10)	Lambert-Eaton Myasthenic Syndrome (LEMS) in adults	Not recommended	119 100	Aug/Sep 2012 Oct/Nov 2010
Amikacin liposomal nebuliser dispersion 590mg (Arikayce®) SMC2432	Treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis. Consideration should be given to official guidance on the appropriate use of antibacterial agents. The addition of amikacin liposomal nebuliser dispersion to standard oral guideline-based therapy for MAC NTM lung infections significantly increased the proportion of patients achieving sputum culture conversion at 6 months and post-treatment at 3 months.	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts - decision expected by May 2022	188	April 2022
Amikacin liposomal nebuliser dispersion 590mg (Arikayce®)SMC2369	Indication under review: Treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis. Consideration should be given to official guidance on the	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative	187	Dec 2021

	appropriate use of antibacterial agents. The addition of amikacin liposomal nebuliser dispersion to standard oral guideline-based therapy for MAC NTM lung infections significantly increased the proportion of patients achieving sputum culture conversion at 6 months and post-treatment at 3 months. The submitting company's justification of the treatment's cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.	medicines.		
amivantamab concentrate for solution for infusion (Rybrevant®) SMC2768	in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).	Not available as not recommended for use in NHS Scotland		
5-aminolevulinic acid 8mg medicated plaster (Alacare®) SMC2353	Single use treatment of mild actinic keratoses lesions with a maximum diameter of 1.8 cm on the face and scalp (hairless areas).	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	185	July 2021
5-aminolaevulinic acid (Ameluz®) (811/12)	Treatment of actinic keratosis of mild to moderate intensity on the face and scalp	Hospital Only (Dermatology Clinic)	123	Jan 2013
amivantamab (Rybrevant) SMC2638	as monotherapy for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.	Not available as not recommended for use in NHS Scotland		
Amlodipine/valsartan (Exforge®) (350/07)	Hypertension	Non-formulary	67	Mar 2007
Anagrelide (Xagrid®)	Thrombocythaemia	Hospital Only	54	2005

			50	
Anakinra 100mg solution for injection in a pre-filled syringe (Kineret®) SMC2449	Treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.	Not available as not recommended for use in NHS Scotland	188	April 2022
Anakinra 100mg/0.67mL solution for injection in pre-filled syringe (Kineret®) SMC2104	In adults, adolescents, children and infants aged eight months and older with a body weight of 10kg or above for the treatment of Still's disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids. Anakinra can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying anti-rheumatic drugs (DMARDs). Anakinra was superior to placebo in achieving a modified American College of Rheumatology paediatric (mACRpedi) 30 response in patients with SJIA reliant on corticosteroids for disease control. Anakinra and DMARDs were associated with a similar remission rate in patients with AOSD following eight weeks of treatment.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	172	Dec 2018
Anakinra (Kineret®) 1116/15	Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above, including: • Neonatal-Onset Multisystem inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA) • Muckle-Wells Syndrome (MWS)	Not Recommended	153	Jan/Feb 2016

	• Familial Cold Autoinflammatory Syndrome (FCAS)			
Anakinra (Kineret®)	Rheumatoid arthritis			2002
Anastrozole (Arimidex®)	ER positive early breast cancer		63 53 37	2006 2005 2004
Andexanet alfa 200 mg powder for solution for infusion (Ondexxya®) SMC2273	For adult patients treated with a direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. In an open-label single-arm study andexanet alfa reduced anti-FXa activity and improved haemostatic efficacy in adults with major bleeds.	Available in line with local guidance for prescribing	181	November 2020
Anidulafungin (Ecalta®) (465/08)	Invasive candidiasis	Hospital Only	85 84 80	Dec 2008 Nov 2008 June 2008
apalutamide 60mg film-coated tablets (Erleada®) SMC2579	in adults for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.		
Apalutamide 60mg film-coated tablets (Erleada®) SMC2472	Treatment of adults with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (ADT). Apalutamide plus ADT significantly improved radiographic progression-free survival (rpfs) and overall survival compared with placebo plus ADT in adults with mhspc.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	191	November 2022
Apalutamide 60mg film-coated	In adult men for the treatment of metastatic hormone-	Not available as not	183	March 2021

tablets (Erleada®) SMC2323	sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy.	recommended for use in NHS Scotland		
Apalutamide 60mg film-coated tablets (Erleada®) SMC2579	In adults for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	194	September 2023
Apixaban 2.5mg and 5mg film-coated tablets (Eliquis®) (836/13)	Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF),	Formulary (Restricted to patients who have poor INR control on warfarin or with allergy to, or incontrollable side effects from coumarin aticoagulants)	125	Mar/Apr 2013
Apixaban, 2.5mg & 5mg, film-coated tablets (Eliquis®) (1029/15)	Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE in adults.	Formulary - Amber 2nd line choice for DVT/PE as an alternative to rivaroxaban	146	Mar 2015
Apixiban (Eliquis®) (741/11)	Prevention of VTE	Not recommended	113	Jan 2012
Apremilast (Otezla®) (1052/15)	For the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA).	Hospital Only Dermatology Clinic Dermatology Specialist List	149	Jun/Jul 2015
Apremilast (Otezla®) (1053/15)	For us alone or in combination with disease modifying anti-rheumatic drugs (DMARDs), for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.	Non Formulary Pending local agreement	149	Jun/Jul 2015
Aprepitant (Emend®)	As part of combination therapy, for the prevention of nausea	Not routinely available as local	163	Sep 2017

80mg,125mg hard capsules , Aprepitant (Emend®) 125mg powder for oral suspension SMC No. (1252/17)	and vomiting associated with highly emetogenic cancer chemotherapy in children, toddlers and infants from the age of six months to <12 years (powder for oral suspension) and adolescents from the age of 12 years to 17 years (hard capsules). SMC has previously accepted aprepitant for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based chemotherapy in adults. The marketing authorisation has since been extended to cover prevention of nausea and vomiting in adults associated with highly emetogenic non-cisplatin based chemotherapy. SMC does not plan to assess this minor licence extension.	clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines		
Aprepitant, 80mg, 125mg hard capsules and 125mg powder for oral suspension (Emend®) SMC No (1241/17)	As part of combination therapy, for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in infants, toddlers and children from the age of six months to less than 12 years (powder for oral suspension) and adolescents from the age of 12 years to 17 years (hard capsules).	Available in line with local guidance for prescribing	162	Aug 2017
Aprepitant (Emend®)	Prevention of cisplatin-induced nausea and vomiting	Hospital Only	46	2004
Aprepitant (Emend®) (242/06)	Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy	Not recommended	112 56	Dec 2011 2006
Argatroban (Exembol®) (812/12)	Anticoagulation in adult patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic therapy	Hospital Only (2nd line)	129 122	Aug/Sep 2013 Dec 2012
Aripiprazole (Abilify Maintena®) (962/14)	Schizophrenia in adults	Hospital Only	138	May/June 2014
Aripiprazole (Abilify®) (891/13)	Moderate to severe manic episodes in Bipolar 1 Disorder in adolescents aged 13 years and older	Hospital Only Child & Adolescent Mental Health Services (CAMHS)	130	Sept/Oct 2013

Aripiprazole (Abilify®) (630/10)	Schizophrenia in adolescents 15 years and older	Hospital Only (Child/adolescent psychiatry)	99 85 52 43	Aug/Sep 2010 Dec 2008 2005 2004
Aripiprazole (Abilify®) orodispersible tablets	Moderate to severe manic episodes in bipolar 1 disorder		90 82	June 2009 Aug/Sep 2008
Asciminib 20mg and 40mg film-coated tablets (Scemblix®) SMC2482	For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP), previously treated with two or more tyrosine kinase inhibitors (TKIs), and without a known T315I mutation. In an open-label, phase III study, asciminib was associated with significantly higher major molecular response rates than another TKI in patients with Ph+ CML-CP who had received at least two previous TKIs and did not have a T315I mutation.	Available in line with national guidance	191	Nov 2022
Arsenic trioxide 1mg/mL concentrate for solution for infusion (Trisenox®) SMC2181	In combination with all-trans-retinoic acid (ATRA [tretinoin]) for the induction of remission, and consolidation in adult patients with newly diagnosed, low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count ≤10 x 103/µl), characterised by the presence of the t(15;17) translocation and/or the presence of the Pro Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	176	Oct 2019
Arsenic trioxide 1mg/mL concentrate for solution for infusion (Trisenox®) SMC2025	In combination with all-trans-retinoic acid (ATRA [tretinoin]) for the induction of remission, and consolidation in adult patients with newly diagnosed, low-to-intermediate risk acute	Not available as not recommended for use in NHS Scotland	173	Mar 2019

	promyelocytic leukaemia (APL) (white blood cell count, ≤10 x 103/µl), characterised by the presence of the t(15;17) translocation and/or the presence of the Pro Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene			
Asenapine (Sycrest®) (762/12)	Treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.	Not recommended	116	Apr/May 2012
Asfotase alfa 40mg/mL and 100mg/mL solution for injection(Strensiq®) SMC 2433		Not available as not recommended for use in NHS Scotland	188	April 2022
Ataluren 125mg, 250mg, and 1,000mg granules for oral suspension (Translarna®) SMC2327	Indication under review: Treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. The presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	184	May 2021
Ataluren 125mg, 250mg, 1,000mg granules for oral suspension (Translarna®) SMC 1131/16	Treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 5 years and older.	Not available as not recommended for use in NHS Scotland	155	June 2016
Atazanavir/cobistat (Evotaz®) (1098/15)	In combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults without known mutations associated with resistance to atazanavir.	Formulary - Hospital Use Only (HIV Clinic)	152	Nov/Dec 2015
Atazanavir (Reeyataz®) (656/10)	HIV	Hospital Only (HIV Clinic)	101 86 85 45	Dec 10/Jan 2011 Jan/Feb 2009 Dec 2008

			44	2004
atezolizumab concentrate for solution for infusion and solution for injection (Tecentriq®) SMC2769	as monotherapy for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapy.	Not available as not recommended for use in NHS Scotland		
Atezolizumab 840mg and 1,200mg concentrate for solution for infusion (Tecentriq®) SMC2492	As monotherapy as adjuvant treatment following complete resection for adult patients with Stage II to IIIA (7th edition of the UICC/AJCC staging system) non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥50% of tumour cells and whose disease has not progressed following platinum-based adjuvant chemotherapy. In an open-label, randomised, phase III study, disease-free survival in patients with stage II to IIIA NSCLC, was significantly longer in patients whose tumours had PD-L1 expression on ≥1% of tumour cells and numerically longer in patients whose tumours had PD-L1 expression on ≥50% of tumour cells with atezolizumab compared with best supportive care. All patients prior to randomisation had disease that had not progressed following adjuvant platinum-based chemotherapy, following complete resection.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	190	August 2022
Atezolizumab 840mg and 1,200mg concentrate for solution for infusion (Tecentriq®) SMC2379		Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	188	April 2021
Atezolizumab (Tecentriq®) 1,200mg concentrate for solution for infusion SMC2349	In combination with bevacizumab for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic	Available in line with local guidance for prescribing	186	Sept 2021

	therapy.			
Atezolizumab 1,200 mg concentrate for solution for infusion (Tecentriq®) SMC2279	Atezolizumab, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).	Available in line with national guidance	182	January 2021
Atezolizumab 840mg concentrate for solution for infusion (Tecentriq®) SMC2267	Atezolizumab in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have programmed death-ligand 1 [PD-L1] expression ≥1% and who have not received prior chemotherapy for metastatic disease.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	182	January 2021
Atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®)SMC2208	In combination with bevacizumab, paclitaxel and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with epidermal growth factor receptor (EGFR) mutant or anaplastic lymphoma kinase (ALK)-positive NSCLC, atezolizumab in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	178	Feb 2020
Atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®) SMC 2254	In combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.	Not available as not recommended for use in NHS Scotland	178	Feb 2020
Atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®) SMC2103	As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma after prior platinum-containing chemotherapy.	Not available as not recommended for use in NHS Scotland	172	Dec 2018
Atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®) SMC No 1336/18	As monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK)-positive tumour	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts- decision	170	Sep 2018

	mutations should also have received targeted therapy before receiving atezolizumab. SMC restriction: treatment with atezolizumab is subject to a two-year clinical stopping rule.	expected by October 2018		
Atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®) SMC No 1297/18	As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma after prior platinum-containing chemotherapy or who are considered cisplatin ineligible.	Not available as not recommended in NHS Scotland	168	May 2018
atidarsagene autotemcel 2 to 10 x 106 cells/mL dispersion for infusion (Libmeldy®) SMC2413	treatment of metachromatic leukodystrophy (MLD) characterized by biallelic mutations in the arylsulfatase A (ARSA) gene leading to a reduction of the ARSA enzymatic activity	Available from a specialist centre in another NHS Board	189	May 2022
atogepant tablets (Aquipta®) SMC2599	"for the prophylaxis of migraine in adults who have at least 4 migraine days per month.	Not routinely available as local implementation plans are being developed	195	December 2023
Atomoxetine (Strattera®) (909/13)	ADHD - adults	Formulary (GP under direction of Mental Health Specialist)	143 132	Nov/Dec 2014 Nov/Dec 2013
Atomoxetine oral solution 4mg/mL (Strattera®) SMC No. 1107/15	Treatment of attention-deficit/hyperactivity disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD. SMC Restriction: to use in patients who are unable to swallow capsules.	Formulary Amber - can be prescribed by General Practice under direction of a specialist	153	Jan/Feb 2016
Atomoxetine (Strattera®)	ADHD - children of 6 years and older or in adolescents	Specialist treatment pathway -	52	2005

		GPs may prescribe under the direction of a specialist in childhood behavioural disorders	49	
Atorvastatin (Lipitor®) (766/12)	Adjunct to diet for reduction of elevated total cholesterol, LDL-cholesterol, apolipoprotein B, and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia including familial hypercholesterolaemia or combined hyperlipidaemia when response to diet and other nonpharmacological measures is inadequate; Reduction of total-C and LDL-C in adults with homozygous familial hypercholesterolaemia as an adjunct to other lipid-lowering treatments or if such treatments are unavailable; Prevention of cardiovascular events in adult patients estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors.	GPs may prescribe under the direction of a paediatric tertiary centre	116	Apr/May 2012
Atorvastatin (Lipitor®)	Hypercholesterolaemia in children		54	2005
Autologous anti-CD19-transduced CD3+ cells (KTE-X19) 0.4 to 2 × 108 cells dispersion for infusion (Tecartus®) SMC2351	The treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor.	Available from a specialist centre in another NHS Board	186	Sept 2021
Avacopan hard capsules (Tavneos®) SMC2578	In combination with a rituximab or cyclophosphamide regimen, for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	195	December 2023
avalglucosidase alfa 100mg powder for concentrate for solution for infusion (Nexviadyme®) SMC2546	long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid α-glucosidase deficiency)	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local		

		preference for alternative medicines.		
Avanafil (Spedra®) (980/14)	Erectile dysfunction in adult men.	Not recommended	139 151	June/July 2014 Sep/Oct 2015
Avalglucosidase alfa 100mg powder for concentrate for solution for infusion (Nexviadyme®) SMC2546	Long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid α-glucosidase deficiency)	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	194	September 2023
avapritinib 100mg, 200mg and 300mg film-coated tablets (Ayvakyt®) SMC2424`	As monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation.		187	Dec 2021
Avatrombopag 20mg film-coated tablets (Doptelet®) SMC2345	Treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. Corticosteroids or immunoglobulins). SMC restriction: to use in patients with severe symptomatic ITP or a high risk of bleeding.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	186	Sept 2021
Avatrombopag 20mg film-coated tablets (Doptelet®) SMC2296	Treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	182	January 2021
Avelumab 20mg/ml concentrate for solution for infusion (Bavencio®) SMC2359	As monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are progression-free following platinum-based chemotherapy.	Available in line with national guidance	186	Sept 2021

Avelumab 20mg/mL concentrate for solution for infusion (Bavencio®) SMC2248	IIn combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). Avelumab plus axitinib, compared with a vascular endothelial growth factor (VEGF)-targeting tyrosine-kinase inhibitor (TKI), improved progression-free survival in adults with advanced RCC.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time	181	November 2020
Avelumab 20mg/mL concentrate for solution for infusion (Bavencio®) SMC No 1315/18	As monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (mMCC).	Available in line with national guidance	169	July 2018
Aviptadil/phentolamine 25 micrograms/2mg solution for injection (Invicorp®) SMC No 1284/17	For the symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic, or mixed aetiology.		166	Feb 2018
axicabtagene ciloleucel dispersion for infusion (Yescarta®) SMC2695	for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.	Available from a specialist centre in another Board		
Axicabtagene ciloleucel dispersion for infusion (Yescarta®) SMC2646	Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.	Not available as not recommended for use in NHS Scotland	196	Feb 2024
Axicabtagene ciloleucel 0.4 – 2 x 108 cells dispersion for infusion dispersion for infusion (Yescarta®) SMC2189	Treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.	Available from a specialist centre in another NHS Board.	177	Dec 2019
Axicabtagene ciloleucel 0.4 – 2 x 108 cells dispersion for infusion dispersion for infusion (Yescarta®) SMC2114	Treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.	Not available as not recommended for use in NHS Scotland	174	May 2019

Axicabtagene ciloleuce SMC2646	Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.		Awaiting publication	January 2024
Axicabtagene ciloleucel dispersion for infusion (Yescarta) SMC2628	For the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.	Not recommended for use in NHS Scotland	197	May/June 2024
Axitinib (Inlyta®) (855/13)	Advanced renal cell carcinoma (RCC)	Hospital Only (Oncology)	132 127	Nov/Dec 2013 May 2013
azacitidine film-coated tablets (Onureg®) SMC2533	maintenance therapy in adult patients with acute myeloid leukaemia who achieved complete remission or complete remission with incomplete blood count recovery following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, haematopoietic stem cell transplantation.	Available in line with national guidance		
Azacitidine (Vidaza®)1175/16	Treatment of adult patients aged 65 years or older who are not eligible for haematopoietic stems cell transplantation (HSCT) with acute myeloid leukaemia (AML with >30% marrow blasts according to World Health Organisation classification).	Not available as not recommended for use in NHS Scotland	156	Sep 2016
Azacitidine (Vidaza®) (589/09)	Adult patients not eligible for haematopoietic SCT with intermediate-2 and high risk MDS, CMML or AML.	Non-formulary - pending protocol	116 110 96	Apr/May 2012 Oct 2011 Apr/May 2010
Azacitidine film-coated tablets (Onureg®) SMC2533	Maintenance therapy in adult patients with acute myeloid leukaemia who achieved complete remission or complete remission with incomplete blood count recovery following induction therapy with or without	Available in line with national guidance	194	September 2023
Azelaic acid (Finacea® 15% Gel) (359/07)	Papulopustular rosacea	Non-formulary	68	May 2007

Azelastine hydrochloride (Dymista® nasal spray) (921/13)	For the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.	Formulary	144 142 133	Jan/Feb 2015 Oct/Nov 2014 Dec 13/Jan 14
Azilsartan medoxomil (Edarbi®) (803/12)	Treatment of essential hypertension in adults	Not recommended	119	Aug/Sep 2012
Azithromycin (Zedbac®) (950/14)	CAP and PID	Hospital Only (Under direction of ID or Microbiology)	137	Apr/May 2014
Azithromycin dihydrate (Azyter®) (804/12)	Conjunctivitis caused by susceptible strains	Not recommended	119	Aug/Sep 2012
Aztreonam lysine (Cayston®) (753/12)	Suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with CF aged 18 years and older	Formulary (GP under direction of specialist in Paediatric or Adult CF Team) (Respiratory Specialist List)	145 115	Feb 2015 Mar/Apr 2012

Updated: 5th June 2025

Back to top Back to homepage